Gland Pharma has reported results for fourth quarter and year ended March 31, 2021.
The company has reported a rise of 33.71% in its net profit at Rs 260.45 crore for the quarter under review as compared to Rs 194.79 crore for the same quarter in the previous year. Total income of the company increased by 37.20% at Rs 934.96 crore for Q4FY21 as compared Rs 681.44 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 33.69% in its net profit attributed to the shareholders at Rs 260.41 crore for the quarter under review as compared to Rs 194.79 crore for the same quarter in the previous year. Total income of the company increased by 37.20% at Rs 934.96 crore for Q4FY21 as compared Rs 681.44 crore for the corresponding quarter previous year.
For the year ended March 31, 2021, the company has reported a rise of 29% in its net profit at Rs 997.01 crore as compared to Rs 772.86 crore for the previous year. Total income of the company increased by 29.77% at Rs 3,597.65 crore for year under review as compared to Rs 2,772.41 crore for year ended March 31, 2020.
For the year ended March 31, 2021, on the consolidated basis, the company has reported a rise of 29% in its net profit attributed to the shareholders at Rs 996.96 crore as compared to Rs 772.86 crore for the previous year. Total income of the company increased by 29.77% at Rs 3,597.65 crore for year under review as compared to Rs 2,772.41 crore for year ended March 31, 2020.
